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Abstract 
Proteolytic cleavage of protein kinase C (PKC) under cell-free conditions generates aco-factor independent, free catalytic subunit (PKM). However, 
the difficulty in visualizing PKM in intact cells has generated controversy regarding its physiological relevance. In the present study, treatment of 
SH-SY-SY cells with 2-0-tetradecanoylphorbol 13-acetate resulted in complete down-regulation of PKC within 24 h without detection of PKM. By 
contrast, low levels of PKM were transiently detected following ionophore-mediated calcium influx under conditions which induced no detectable 
PKC loss. PKM was not detected uring rapid cell-free degradation of partially purified SH-SY-SY PKCa by purified human brain mM calpain. 
However, when the kinetics of PKC degradation were slowed by lowering levels of calpain, PKM was transiently detected. PKM was also only 
transiently observed following calpain-mediated degradation of purified rat brain PKCa. Densitometric analyses indicated that, once formed, PKM 
was degraded approximately 10 times faster than PKC. These data provide an explanation as to why PKM is difficult to observe in situ, and indicate 
that PKM should not be considered as an ‘unregulated’ kinase, since its persistence is apparently strictly regulated by proteolysis. 
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1. Introduction 
The Ca’+, phospholipid-dependent kinase, protein ki- 
nase C (PKC), is a family of related enzymes that medi- 
ate transmembrane signaling (for review, see [l]). The 
different PKC isoforms display differential spatial and 
temporal localization in neurons [2-51, demonstrate dis- 
tinct substrate requirements [6] and mediate different 
functions (e.g. [7-111. PKC is reversibly activated by 
1,2-diacylglycerol (DAG), which is generated by recep- 
tor-mediated inositol phospholipid hydrolysis by phos- 
pholipase C. DAG stabilizes a complex consisting of 
PKC and membrane phospholipid. Inositol 1,4,5-tris- 
phosphate, the other product of the phosphoinositide 
hydrolysis, mobilizes Ca 2+ from intracellular stores, 
which associates with the DAG-membrane-PKC com- 
plex. In the presence of DAG, the Ca2’- requirement for 
PKC activation is lowered, resulting in a synergistic ef- 
fect between these two second messenger molecules. 
Phosphorylation of a distinct set of proteins then ensues 
(for reviews of these processes, see [12,13]). 
Mobilization of intracellular Ca2+ also activates the 
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calcium activated protease, calpain, which translocates 
to the plasma membrane. Calpain then irreversibly acti- 
vates PKC by cleavage of the catalytic and regulatory 
subunits, generating a soluble, Ca2’- and phospholipid- 
independent form, termed PKM, which migrates on 
SDS-gels in various studies from 46-50 kDa [12,1420]. 
The respective roles of these two methods of PKC activa- 
tion remain unclear. Some (e.g. [l&19]), but not all (e.g. 
[21]) PKC-mediated processes are blocked by protease 
inhibitors such as leupeptin, suggesting that proteolysis 
may be required for certain PKC functions (for review, 
see [12]). Since the regulatory subunit, rather than the 
catalytic subunit, contains the lipid-sensitive calcium- 
binding domain [22], PKM, unlike the membrane- 
bound, calcium-dependent ative enzyme, has potential 
access to, and can phosphorylate a distinct set of non- 
membrane-associated protein substrates [ 191. Genera- 
tion of inappropriate PKM levels as a consequence of 
hyperactivation of calpain has been considered as poten- 
tially contributing to certain neurodegenerative condi- 
tions (e.g. see [23,24]). 
Exposure of most cell systems to the PKC activator 
12-0-tetradecanoylphorbol 13-acetate (TPA), a DAG 
analog that activates PKC by mimicking DAG-induced 
stabilization of PKC at the plasma membrane, causes 
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translocation of the entire PKC content of the cell to the 
membrane and ultimate down-regulation of the enzyme. 
Proteolysis has been shown to be an essential factor in 
this down-regulation [18,2.5]. However, PKM is not ob- 
served under these conditions. An exception is when cells 
are exposed to calcium ionophore, Ca2’ and TPA, which 
causes the rapid conversion of nearly all PKC to PKM 
[18-201. The contrast between the routine observation of 
PKM under cell-free conditions with the difficulty of 
PKM detection within intact cells has generated contro- 
versy regarding the physiological relevance of PKM. An 
additional possibility is that PKM may itself be subject 
to additional proteolytic events, and therefore does not 
accumulate under physiological conditions (e.g. see [ 121). 
We have attempted to resolve this controversy using SH- 
SYSY human neuroblastoma cells, which we have previ- 
ously shown to express both ,uM and mM calcium-re- 
quiring calpain isoforms and the a, p, 6, e and y isoforms 
of PKC [3,8,2&28]. In this paper we provide evidence 
that PKM derived from PKCol is degraded by mM cal- 
pain, and furthermore that, once formed, this free cata- 
lytic subunit is degraded at a rate faster than that of the 
native PKCa. 
2. Materials and methods 
2.1. Culture conditions and treatment with calpain and kinase inhibitors 
and activators 
SH-SY-5Y cells (originally obtained from the stocks of Dr. June L. 
Biedler, Memorial Sloan-Kettering Cancer Center, NY) were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal 
calf serum (FCS) at 37°C in a humidified atmosphere containing 10% 
CO,. Twenty-four hours later, the medium was replaced with medium 
containing FCS with either no further additions or TPA (1 PM) for 
various times from 5 min to 24 h. Influx of calcium into intact cells was 
achieved by addition of 3 PM calcium ionophore A231 87 directly into 
cultures in DMEM, which contains 1.8 mM CaCl, [29]. Culture media, 
FCS, TPA and ionophore were purchased from Sigma Chemical Co. 
(St. Louis, MO). Cells were dislodged by scraping with a rubber police- 
man, homogenized and centrifuged to yield particulate and supernatant 
fractions as previously described [27]. 
2.2. Partial purification of mM calpain and PKC 
mM calpain was purified 950-fold from post-mortem human brain 
by sequential chromatography on DE-52 cellulose, phenyl Sepharose 
and Ultrogel-AcA-A4 as previously described [30]. PKC was enriched 
from the supernatant fraction (above) generated from untreated SH- 
SY-5Y cells by DE-52 cellulose chromatography as previously de- 
scribed [3]. 
2.3. Incubation of purt$ed PKC and cellular fractions with mM calpain 
Aliquots (containing 100 pg of total protein) of PKC-containing 
DEAE column fractions from SH-SY-5Y cells or purified PKCa (1 pg; 
UBI Inc., Lake Placid, NY) were diluted in 50 mM Tris-HCI (pH 7.4) 
containing 2 mM PMSF and either immediately placed on ice (0 time) 
or were incubated at 30°C with and without various combinations of 
5 mM EDTA. 2 mM CaCl,. and 21.2-85 ng of aurified caloain for 
various time intervals as indicated, after which samples were immedi- 
ately placed on ice and received Laemlli treatment buffer for subsequent 
electrophoresis or were immediately assayed for PKM activity as de- 
scribed below. 
2.4. Gel electrophoresis and immunoblot analysis 
Samples were electrophoresed on SDS 7% polyacrylamide gels and 
transferred to nitrocellulose in a Hoefer Transphor apparatus as de- 
scribed [31]. The co-migration of calpain (76-80 kDa) and PKC (80 
kDa) necessitated the use of immunoblot methodologies to monitor 
proteolytic degradation of PKC. Nitrocellulose replicas were probed 
with a 1: 100 dilution of a commercial monoclonal antibody that specif- 
ically recognizes the catalytic domain of PKCa (UBI) followed by 
reaction with alkaline phosphatase-conjugated goat anti-mouse anti- 
body and visualization as described [31]. This antibody therefore per- 
mitted the simultaneous visualization of PKC and PKM. In the present 
study, we have utilized a monoclonal antibody that specifically recog- 
nizes the catalytic domain of PKCa; accordingly, results presented 
herein are only for that isoform. Since evidence is accumulating that the 
various PKC isozymes display unique neuronal localizations and sensi- 
tivities and mediate distinct functions (see refs. in section I), it should 
be considered that the other PKC isoforms [17], and any respective 
PKM derived from them, may display distinct degradation profiles 
[32,33]. Due to the difficulty in visualizing PKM in intact cells and 
fractions, alkaline phosphatase was routinely utilized as chromogen, 
since it afforded the maximal PKM visualization. 
2.5. Densitometric analysis of nitroceihdose replicas 
Nitrocellulose replicas were scanned at optimal contrast within a 
linear range using a Hewlett-Packard ScanJet Ilp scanner connected to 
a Macintosh MacPlus computer, and resulting digitized immunoblot 
profiles were compared with the Scan Analysis densitometric program 
(BioSoft, Ferguson, MO) and values were exported into Statworks and 
Cricket Graph software as described [34]. The value obtained for PKC 
at 0 incubation time for each nitrocellulose replica was defined as lOO%, 
and all additional immunoreactive PKC and PKM bands on each 
respective replica were calculated as percentages relative to their respec- 
tive PKC value at time 0. The relative rates of decrease in purified PKC 
and PKM immunoreactivity between 2 and 10 min was obtained by 
subtraction of each data set (i.e. (relative densitometric value at 2 min) 
- (densitometric value at 10 min)) from individual densitometric anal- 
yses, and the mean + S.E.M. was then determined for the grouped 
differences; this procedure was carried out separately for PKC and 
PKM. Representative nitrocellulose replicas are presented, and accom- 
panying graphs present values obtained from the respective nitrocellu- 
lose replica; all experiments were carried out at least twice with identical 
profiles. It should be noted that the relative affinity of this monoclonal 
antibody for the native enzyme (PKC) versus the proteolytically cleaved 
catalytic domain (PKM) is not known and therefore cannot be com- 
pared. Calculation of PKM as a percentage of PKC at time 0 serves 
only as a reference point for construction of graphs, since in many 
instances there is no detectable PKM at time 0. In this study, no attempt 
is made to compare the absolute amount of PKM immunoreactivity 
with that of PKC; the relative presence of PKM or PKC are separately 
evaluated by their respective immunoreactivities during incubation 
with calpain. 
2.6. PKC activity assay 
PKC activity in supernatant fractions derived from untreated and 
ionophore-treated SH-SY-5Y cells, and in purified PKC samples fol- 
lowing incubation with calpain was assayed using a commercially- 
available PKC assay system (Gibco, New York) based on incorpora- 
tion of [y-“P]ATP (DuPont-NEN, Boston, MA) into a synthetic 
peptide corresponding to a fragment of myelin basic protein (MBP, ,4) 
in the absence of lipids, CaCl, and diolein according to the manufac- 
turer’s instructions (e.g. see [35]). In some SH-SY-5Y supernatant frac- 
tions, 5 mM EDTA was added in these assays to chelate any free CaC&. 
3. Results 
Treatment of intact SH-SY-SY cells with TPA results 
in the rapid translocation of PKC to the plasma mem- 
brane, followed by complete down-regulation within 24 
h (Fig. 1). PKM immunoreactivity was not detected ur- 
ing this translocation and down-regulation (Fig. l), nor 
was it transiently detected at earlier time points (e.g. I-30 
min) during TPA treatment (not shown). By contrast, 
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Fig. 1. Nitrocellulose replica of SH-SY-5Y cellular fractions immunostained with an anti-PKC monoclonal antibody that recognizes the catalytic 
domain of PKCa. Cells were exposed to 1 ,BM TPA in culture medium and incubated for 0, 1, 4 and 24 h as indicated, after which cells were 
homogenized and subjected to centrifugation to yield particulate and supernatant fractions as described in section 2. The migratory positions of PKC 
(80 kDa) and PKM (46 kDa) are indicated. Note the translocation of virtually all of the PKC content of the cell to the particulate fraction within 
1 h of TPA treatment, and the subsequent down-regulation of PKC over 24 h. Note also the lack of PKM immunoreactivity before and during this 
treatment. 
however, ionophore-mediated calcium influx into intact 
cells did generate detectable PKM, but only in minor 
amounts (Fig. 2). PKM immunoreactivity was first de- 
tected in particulate fractions after 5 min, followed by a 
rapid decrease and loss from this fraction within 30 min. 
This decrease coincided with the transient appearance of 
PKM at 15 min within the supernatant fraction. PKM 
immunoreactivity also decreased within the supernatant 
compartment by 30 min. No significant ranslocation of 
PKC to the plasma membrane, nor any overall decrease 
in PKC immunoreactivity, was apparent during this 30 
min incubation with ionophore; densitometric analysis 
(not shown) confirmed the lack of decrease PKC im- 
munoreactivity. It should be noted that the nitrocellulose 
replica presented in Fig. 2 represents a favorable image, 
and in many instances, significantly less PKM was ob- 
served. Low but significant levels of co-factor independ- 
ent phosphorylation of the specific PKC substrate 
MBP,,, were observed when this fragment was incu- 
bated in cell-free assays with SH-SY-5Y supernatant 
fractions, providing additional evidence for at least some 
PKM generation within SH-SY-5Y cells. In the absence 
of added PKC co-factors or activators (phosphatidyl 
Particulate 
0 5 10 15 30 
serine, DAG, TPA) and in the presence of 5 mM EDTA, 
1277.3 + 157.0 cpm were incorporated into filter-precip- 
itable material within 5 min in supernatants to which 
MBPw was added versus a ‘background’ of 
876.8 + 65.1 cpm incorporated into phosphocellulose- 
bound material in supernatants not receiving MBP4-i4; 
Since levels of phosphorylation of supernatants from 
cells not treated with ionophore were defined as baseline 
for each condition, this difference (approx. 400 cpm) 
therefore represents PKM-mediated phosphorylation of 
MBP,,,. 
The transient appearance of PKM following iono- 
phore-mediated calcium influx into intact cells and the 
only a modest increase in MBP,,, phosphorylation sug- 
gested that PKM may also be subjected to rapid prote- 
olytic degradation within intact cells. To examine this 
possibility, PKC enriched from the soluble fraction of 
SH-SYSY cells was exposed to purified human brain 
mM calpain, which rapidly degraded nearly all of the 
PKC. By contrast, no significant loss of PKC im- 
munoreactivity, nor any increase in PKM immunoreac- 
tivity, was observed when these fractions were incubated 
for as long as 24 h in the absence of calpain and only 
Supernatant 
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Fig. 2. Nitrocellulose replica of SH-SY-SY cellular fractions immunostained with an anti-PKC monoclonal antibody that recognizes the catalytic 
domain of PKCa. Cells were exposed to 3 PM calcium ionophore A23 187 in culture medium and incubated for O-30 min as indicated, after which 
cells were homogenized and subjected to centrifugation to yield particulate and supernatant fractions as described in section 2. The migratory positions 
of PKC (80 kDa) and PKM (46 kDa) are indicated. Note the appearance of PKM immunoreactivity in particulate fractions after 5 min of incubation, 
the subsequent decrease and loss from this fraction within 30 min, the transient appearance of PKM at 15 min within the supernatant, and the loss 
of PKM from the supernatant was evident by 30 min. Note also the lack of significant translocation of PKC to the plasma membrane, nor any overall 
decrease in PKC immunoreactivity. 
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Fig. 3. Nitrocellulose replica of PKC-enriched DEAE column fractions 
obtained from supematant fractions of untreated SH-SY-SY cells and 
incubated with purified mM calpain for 0 or 24 h as described in section 
2. Replicas were immunostained with an anti-PKC monoclonal anti- 
body that recognizes the catalytic domain of PKCa. The migratory 
positions of PKC (80 kDa) and PKM (46 kDa) are indicated. Note the 
loss of PKC immunoreactivity only following incubation with calpain 
and CaCl,. 
slight loss was observed after 24 h in the presence of 
calpain but in the absence of CaCl, (Fig. 3, see also [28]). 
These data demonstrated the absence of any protease 
activity directed against PKC in these fractions, and fur- 
ther confirmed the ability of human brain calpain to 
degrade PKC isolated from SH-SY-5Y cells. Despite 
proteolysis of nearly all of the PKC, the lack of signifi- 
cant accumulation of PKM immunoreactivity (Fig. 3) 
suggested that PKM was also undergoing proteolysis. To 
examine this phenomenon more closely, we altered the 
kinetics of PKC degradation by exposing a constant 
amount of PKC-enriched column fractions from SH- 
SY-5Y cells to varying amounts of mM calpain for O-15 
min and assayed for the presence of PKC and PKM by 
immunoblot analysis under otherwise identical incuba- 
tion conditions (Fig. 4). Incubation of PKC-enriched 
fractions with 85 ng of mM calpain resulted in the degra- 
dation of approximately 75% of the PKC within 15 min; 
PKM was not detected at any time under these condi- 
tions. Decreasing the calpain concentration in the incu- 
bation to 65 ng substantially lessened the extent of PKC 
degradation; only 25% of the PKC immunoreactivity 
was lost by 15 min. However, transient low levels of 
PKM immunoreactivity were now detected, with a peak 
at 5 min of incubation. Decreasing the calpain to 42.5 ng 
resulted in loss of only approximately 10% of the PKC 
immunoreactivity, yet yielded relatively more PKM than 
did 65 ng of calpain, although PKM was still transient 
and was lost by 15 min. Finally, PKM was not observed, 
and no PKC immunoreactivity was lost, when calpain 
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was decreased to 21.2 ng. Increased but transient obser- 
vation of PKM following the progressive reduction in 
calpain activity suggests that, once formed, PKM may 
represent a preferred substrate for mM calpain than in- 
tact PKC. 
These findings in intact cells and cellular fractions 
were substantiated by similar analyses with purified 
PKCol. As with cellular fractions (above), no loss of 
purified PKCa, nor increase in PKM, was observed dur- 
ing a 60 min incubation in the absence of calpain (not 
shown). However, PKCcl was rapidly degraded follow- 
ing incubation with 65 ng mM calpain in the presence of 
CaCl, (Fig. 5); densitometric analysis revealed an ap- 
proximate 80% decrease in PKC immunoreactivity 
within 2 min of incubation. This loss of PKC was not 
accompanied by PKM accumulation; rather, it was ac- 
companied by the transient appearance of PKM im- 
munoreactivity and activity, as demonstrated by im- 
munoreactivity at 46 kDa and the corresponding tran- 
sient appearance of co-factor independent phosphoryla- 
tion of MBPk,4, respectively (Fig. 5). Densitometric 
analyses of PKM immunoreactivity revealed a time 
course similar to that of PKM-mediated MBP,,, phos- 
phorylation. These data confirm that human brain mM 
calpain can generate PKM from PKC by limited proteol- 
ysis, and that PKM is also subsequently degraded by 
mM calpain. The failure of PKM to have accumulated 
at larger levels following 2 min of incubation with cal- 
pain, during which approximately 80% of the PKC im- 
munoreactivity was lost, coupled with the subsequent 
transient observation of PKM further suggested that, 
once formed, PKM is degraded at least as fast, if not 
faster, than PKC; shorter incubation times (e.g. 30 s-l 
min) did not reveal a transient higher level of PKM (not 
shown). Therefore, in order to examine further the rela- 
tive degradation rates of PKC and PKM, we separately 
compared the difference in densitometric values obtained 
for PKC and PKM at 2 min (i.e., the observed peak of 
PKM immunoreactivity and activity) and 10 min (the 
last point examined in these an analyses) of incubation 
in 6 separate scans. PKM immunoreactivity between 2 
and 10 min decreased by 9.6 f. 1.3% (mean ? S.E.M.), 
yet PKC immunoreactivity did not decrease further dur- 
ing this time (+0.4 L- 1.2); it should be noted that the 
decrease in PKM represents a conservative estimate, 
since at least some PKM may theoretically still be gener- 
ated by PKC degradation during the 10 min incubation. 
These comparisons of densitometric data of purified pro- 
teins indeed suggest that PKM is degraded by mM cal- 
pain at a faster rate than PKC. 
4. Discussion 
While numerous studies in cell-free systems have dem- 
onstrated that limited proteolysis of PKC generates a 
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Fig. 4. Nitrocellulose replica of PKC-enriched DEAE column fractions obtained from supematant fractions of untreated SH-SY-SY cells and 
incubated with various concentrations of purified mM calpain as described in section 2. Replicas were immunostained with an anti-PKC monoclonal 
antibody that recognizes the catalytic domain of PKCa. The migratory positions of PKC (80 kDa) and PKM (46 kDa) are indicated. The graph 
accompanying each replica presents corresponding numerical values obtained by densitometric analysis of the respective replica. Note the following: 
the loss of approximately 75% of the PKC immunoreactivity within 15 min, and the lack of PKM immunoreactivity, following incubation with 85 
ng calpain; the loss of approximately 25% of the PKC immunoreactivity and the transient appearance of PKM immunoreactivity following incubation 
with 65 ng calpain; the loss of approximately 10% of the PKC immunoreactivity and a transient appearance of PKM immunoreactivity following 
incubation with 42.5 ng calpain; and finally, the lack of PKC loss of PKC immunoreactivity, and lack of appearance of PKM immunoreactivity, 
following incubation with 21.2 ng calpain. Note also the apparent increase in the amount of PKM transiently obtained following incubation ofcellular 
fractions with 42.5 ng calpain versus that obtained with 65 ng calpain. 
co-factor-independent, free catalytic subunit (‘PKM’), not PKM indeed exists within intact cells is of consider- 
the difficulty to demonstrate the presence of PKM in able importance in understanding the full nature and 
intact cells has generated controversy concerning the extent of the roles of PKC in situ, since PKM can theo- 
physiological relevance of this process [12]. Whether or retically act on additional classes of substrates that are 
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Fig. 5. Analysis of purified PKCa incubated for O-10 min with purified 
mM calpain as described in section 2. Nitrocellulose replicas were 
immunostained with an anti-PKC monoclonal antibody that recognizes 
the catalytic domain of PKCcz. A representative replica, with the migra- 
tory positions of PKC (80 kDa) and PKM (46 kDa) indicated, is 
presented in the center panel. The top panel presents densitometric 
analysis of immunoblots. Values are presented as the mean + S.E.M. 
for 6 separate scans; data points in which error bars are not detected 
indicates that the S.E.M. is contained within the respective graph point. 
The bottom panel presents co-factor-independent (i.e. PKM-mediated) 
incorporation of [Y-‘~P]ATP into a synthetic MBP peptide fragment 
obtained following incubation of this fragment with the above calpain- 
treated PKC samples as described in section 2. 
inaccessible to its membrane-associated, co-factor-de- 
pendent parent enzyme [19]. The findings of the present 
study indicate that PKM is indeed formed in intact neu- 
ronal cells as a consequence of limited mM calpain-medi- 
ated proteolysis of PKC. Our findings further indicate 
that a major factor in the difficulty of visualizing PKM 
is that the free catalytic subunit is degraded at a faster 
rate than the native enzyme; indeed, only by slowing 
down the kinetics of mM calpain-mediated PKC proteo- 
lysis were we reproducibly able to visualize PKM even 
in cell extracts; the transient observation of PKM im- 
munoreactivity in neutrophils, and furthermore only 
under certain experimental conditions [20], is consistent 
with these findings. 
The findings of the present study substantiate the tran- 
sient formation of PKM in neuronal cells; the observa- 
tion of PKM initially within the particulate fraction, 
followed by its loss from that fraction and appearance 
in the supernatant fraction indicates, as previously sug- 
gested by others (for review, see [12]) that PKM is 
formed at the plasma membrane and, since it lacks a 
lipid-binding domain, migrates into the cytosol. Our vis- 
ualization of PKM was likely to be facilitated by the use 
of a monoclonal antibody that recognizes an epitope 
within the catalytic subunit; a similar experimental ap- 
proach, i.e. using a monoclonal antibody that recognizes 
both PKC and PKM also demonstrated the transient 
appearance of PKM in human neutrophils [20]. These 
data do not confirm the physiological significance of 
PKM, which would require the demonstration of PKM- 
specific substrate phosphorylation in situ. In addition, 
these studies do not address whether or not additional 
proteases are active against PKC and/or PKM, and 
whether or not alternative methods of PKC activation, 
or alternative cleavage patterns, can result in PKC down- 
regulation without generating PKM. Indeed, PKM was 
not visualized in SH-SY-5Y cells during TPA-mediated 
PKC activation and ultimate down-regulation in the 
present study, nor following TPA treatment of neutro- 
phils [20]. While it has been shown that proteolysis of 
PKC is a necessary component of TPA-mediated PKC 
down-regulation [l&25], it remains to be determined 
whether or not significant levels of PKM are transiently 
generated during this process. Finally, it is yet unclear 
whether or not PM calpain, mM calpain or both are 
responsible for in situ proteolysis of PKC, although both 
calpain isoforms readily degrade PKC and PKM in cell- 
free studies (Shea et al., unpublished). 
An important implication of the findings of the present 
study is that PKM, although co-factor-independent and 
not restricted to the plasma membrane, should not be 
considered to be an ‘unregulated’ kinase; in fact, our 
data showing that PKM is degraded faster than PKC 
demonstrate that PKM is actually under tight regulation 
by calpain-mediated proteolysis. The same reasoning 
holds in other cell systems where PKM may not be de- 
graded faster than, but rather a rate similar to that of, 
PKC. Accordingly, rapid elimination of PKM by calpain 
and/or additional proteases would normally circumvent 
excessive phosphorylation of potentially inappropriate 
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substrates. An additional interpretation of the present 
findings is that disregulations in proteolytic activities 
that may accompany certain pathophysiological condi- 
tions may give rise to the persistence of excessive PKM 
[23,24]. Related studies in SH-SY-SY cells indicate that 
ionophore-mediated calcium influx across the plasma 
membrane selectively activates membrane-associated, 
but not cytosolic, ,uM calpain [28]. Accordingly, calcium 
influx and consequent hyperactivation of plasma mem- 
brane-associated calpain at the plasma membrane could 
rapidly generate PKM in amounts exceeding that which 
membrane-associated calpain could degrade further. 
Consequently, excessive amounts of PKM may enter the 
cytosolic compartment and initiate phosphorylation of 
inappropriate substrates, and/or hyperphosphorylation 
of otherwise normal substrates. The potential role of 
excessive PKM generation or persistence in the patho- 
genesis of certain conditions remains an important area 
of investigation. 
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